AUR-VCS-2021-03: A Prospective Observational Registry of Patients Treated with LUPKYNIS (voclosporin) in the US

About this Study

The purpose of this registry is to assess the use and effectiveness of LUPKYNIS in patients with lupus nephritis.

Sponsor Protocol ID:AUR-VCS-2021-03
IRB Number:2022-259
Actively Enrolling
Interventional
Observational/Not Applicable
August 15, 2022
Eligibility Criteria
18 years old
Both Male and Female
No
No
No

Inclusion Criteria
  • Male or female age 18 or older
  • Lupus nephritis (LN) confirmed by biopsy within 24 months prior to enrollment
  • Initiating or have initiated treatment with commercial LUPKYNIS as per the US approved Prescribing Information within the 3 months prior to consent
  • Have access to US healthcare insurance
  • Able to understand and sign informed consent

Exclusion Criteria
  • Use of LUPKYNIS outside of the approved US Prescribing Information

Categories Click category to view its trials.
Arthritis/Rheumatology
Participating Locations
Pavilion - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Delia Owens
Phone Number: 601-815-9231
Email: dyowens@umc.edu
Principal Investigator:Lee Ching, Cathy P, M.D.
How to participate in our Clinical Trials